Moderna receives US FDA approval for COVID-19 vaccine mNEXSPIKE

Moderna

31 May 2025 - mNEXSPIKE becomes Moderna's third FDA approved product.

Moderna today announced that the US FDA has approved mNEXSPIKE (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention.

Read Moderna press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , US , Vaccine , COVID-19